Surgery Partners (NASDAQ:SGRY) Beats Q2 CY2026 Sales Expectations
Surgery Partners (NASDAQ: SGRY) reported Q2 CY2026 revenue of $848.9 million, up 2.7% year over year, beating Wall Street’s estimate by 2.2%. The company forecast full-year revenue around $3.4 billion. Non-GAAP EPS was $0.10, clearing consensus, and full-year EPS is expected to rise from $0.32 to $0.56.
How this was made
The 30-second read
Why it matters
The key tradable inputs are the Q2 revenue and EPS beats versus consensus, the reiterated full-year revenue expectation near $3.4B, and the offsetting year-over-year declines in adjusted EPS and adjusted operating margin.
Market read
A company-specific earnings beat with guidance near consensus can drive short-term positioning, but margin and EPS contraction raise questions about sustainability.
What to watch
The article cites a pending Idaho Falls transaction and portfolio optimization, but provides no deal economics; traders may need to discount the guidance until transaction terms and integration timelines are clearer.
Background
Surgery Partners operates outpatient surgical facilities and short-stay surgical hospitals across 33 states, positioning itself around ASC market growth and portfolio optimization.
Ticker impact
Surgery Partners reported Q2 CY2026 revenue of $848.9M (+2.7% YoY) and non-GAAP EPS of $0.10, beating consensus estimates.
Likely modest upside bias for the next few sessions, with follow-through dependent on whether investors focus on margin contraction and EPS deceleration.
The article provides concrete earnings beats and full-year revenue guidance, but also notes adjusted operating margin and adjusted EPS declined year over year, which can cap the upside.
Market effects
Reinforces demand and execution strength in the ASC/short-stay surgical facility model, but margin pressure highlights cost sensitivity in healthcare services.
No specific regional read-through beyond the company’s multi-state footprint.
Limited, as the disclosure is company-specific within US healthcare services.
Counterpoint
The beat may be less durable because adjusted operating margin fell and adjusted EPS declined YoY, suggesting the quality of earnings could be weaker than the headline beat implies.
Key entities
- public_companySurgery Partners
NASDAQ-listed healthcare services provider reporting Q2 CY2026 results and full-year revenue outlook.
- executiveEric Evans
CEO quoted on progress, portfolio optimization, and the pending Idaho Falls transaction.
